Advanced Analysis Free Trading Signals Real Time Alerts

Oxford Biomedica Shares Rally After Upgrading Revenue Guidance

Practice Stock Trading Your capital is at risk
Updated: 18 May 2021

Shares of Oxford Biomedica (LON: OXB) are climbing on Tuesday after the company said it is raising revenue guidance.

The announcement results from the company updating the 18 month supply agreement it signed with AstraZeneca (LON: AZN) in September 2020.

“Following successful manufacture of large-scale batches of AstraZeneca's COVID-19 Vaccine, AstraZeneca has today committed to an increase in the number of batches required from Oxford Biomedica in the second half of 2021,” stated Oxford Biomedica.


The news has seen the company raise its revenue guidance for expected cumulative revenues from AstraZeneca by the end of 2021 from over £50 million to more than £100 million.

The gene and cell therapy company now expects “significant” growth in its group operating EBITDA for the year ending 2021.

Oxford Biomedica's share price has jumped over 6.2% on the news to 1,064p per share.

Should You Invest in Oxford Biomedica Shares?

One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 68 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .